1xbet 온라인., Ltd.

Otsuka Pharmaceutical Co. Ltd. announces that Avanir Pharmaceuticals, Inc., a U.S. subsidiary based in Aliso Viejo, California, received a favorable ruling from 1xbet 온라인 U.S. Court of Appeals regarding NUEDEXTA^®. 1xbet 온라인 Federal Circuit Court upheld 1xbet 온라인 validity and enforceability of Avanir's patents covering NUEDEXTA (U.S. patent numbers 7,659,282 and 8,227,484). 1xbet 온라인 decision confirms patent protection in 1xbet 온라인 U.S. for NUEDEXTA until 2026.

1xbet 온라인 Appeals Court ruling affirmed 1xbet 온라인 April 2014 decision upholding 1xbet 온라인 two patents' validity by 1xbet 온라인 U.S. District Court for 1xbet 온라인 District of Delaware in a lawsuit brought by Avanir against 1xbet 온라인 generic manufacturer Par Pharmaceuticals.

NUEDEXTA is an innovative combination of two well-characterized components, dextromethorphan hydrobromide, 1xbet 온라인 ingredient active in 1xbet 온라인 central nervous system, and quinidine sulfate, a metabolic inhibitor enabling 1xbet 온라인rapeutic dextromethorphan concentrations. Dextromethorphan acts on sigma-1 and NMDA receptors in 1xbet 온라인 brain, although 1xbet 온라인 mechanism by which NUEDEXTA exerts 1xbet 온라인rapeutic effects in patients with pseudobulbar affect (PBA) is unknown.

PBA occurs secondary to a variety of o1xbet 온라인rwise unrelated neurologic conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to 1xbet 온라인 underlying emotional state.

NUEDEXTA is 1xbet 온라인 only U.S. FDA-approved product for 1xbet 온라인 treatment of pseudobulbar affect.

• Note: this press release was issued by Avanir Pharmaceuticals in 1xbet 온라인 U.S. on August 11, 2015